| JaLCDOI | 10.18926/AMO/56464 |
|---|---|
| FullText URL | 73_1_85.pdf |
| Author | Abe, Yoshiyuki| Fujibayashi, Kazutoshi| Nishizaki, Yuji| Yanagisawa, Naotake| Nojiri, Shuko| Nakano, Soichiro| Tada, Kurisu| Yamaji, Ken| Tamura, Naoto| |
| Abstract | Pneumocystis pneumonia (PCP) due to Pneumocystis jirovecii infection is the leading cause of fatal opportunistic infections in immunocompromised patients. We will determine whether a daily sulfamethoxazole-trimethoprim (SMX/TMP) dose of 200/40 mg was non-inferior to 400/80 mg for PCP prevention in patients with systemic rheumatic disease under immunosuppressive therapy. This is a randomized, open-label, multicenter controlled trial. The primary outcome is the rate of PCP prevention at 52 weeks. The secondary outcome is the discontinuation rate of SMX/TMP. The trial will evaluate the optimal dose of SMX/TMP for PCP prevention in patients with systemic rheumatic disease under immunosuppressive therapy. |
| Keywords | pneumocystis pneumonia prophylaxis systemic rheumatic disease sulfamethoxazole-trimethoprim conventional-dose versus half-dose |
| Amo Type | Clinical Study Protocol |
| Published Date | 2019-02 |
| Publication Title | Acta Medica Okayama |
| Volume | volume73 |
| Issue | issue1 |
| Publisher | Okayama University Medical School |
| Start Page | 85 |
| End Page | 89 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | CopyrightⒸ 2019 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 30820060 |
